iShares US Pharmaceuticals ETF
91 hedge funds and large institutions have $205M invested in iShares US Pharmaceuticals ETF in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 47 reducing their positions, and 23 closing their positions.
12% less funds holding
Funds holding: 103 → 91 (-12)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25.68% less ownership
Funds ownership: 123.06% → 97.38% (-26%)
43% less capital invested
Capital invested by funds: $358M → $205M (-$153M)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
72% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAMA
EFG Asset Management (Americas)
Miami,
Florida
|
+$7.62M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.13M |
| 3 |
Jane Street
New York
|
+$3.73M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.17M |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$22.1M |
| 2 |
Goldman Sachs
New York
|
-$21M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$11.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$10.4M |
| 5 |
LPL Financial
San Diego,
California
|
-$7.59M |
IHE Hedge Fund Activity: Q1 2016 in Review
91 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2016, worth a combined $205M — down 43% from $358M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IHE and 11 opened new positions — a net loss of 12 holders — while 47 trimmed existing stakes and 13 added.
The largest buyer was EFG Asset Management (Americas), opening a new position worth an estimated $7.62M. The largest seller was Morgan Stanley, cutting an estimated $22.1M.
- 91 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2016, down from 103 in Q4 2015.
- Funds reported $205M of iShares US Pharmaceuticals ETF stock for Q1 2016, down 43% quarter-over-quarter.
- 11 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2016 and 23 closed out, a net change of -12 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2016 was EFG Asset Management (Americas), an estimated $7.62M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2016 was Morgan Stanley, an estimated $22.1M sold.
Based on aggregated 13F filings for Q1 2016.